How do the QUARTZ trial results inform future research for patients with brain metastases from non-small cell lung cancer? by Nankivell, M et al.
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2017;6(Suppl 2):S446-S447 tcr.amegroups.com
We read with interest the editorial by Tsao (1), and thank 
the author for this well considered response to our recent 
paper describing the results of the QUARTZ trial of whole 
brain radiotherapy for patients with inoperable brain 
metastases from non-small cell lung cancer (2). We continue 
to be encouraged by the amount of discussion taking place 
surrounding treatment options for these patients.
Tsao rightly highlights that it was very challenging 
to recruit patients into QUARTZ. Diagnoses such as 
inoperable brain metastases are clearly very distressing and 
present a difficult setting in which to conduct a clinical trial. 
We would like to express our sincere thanks and admiration 
for the patients and clinicians who persevered with the trial 
and made it a success. We largely agree with the author 
that the lack of clinical equipoise in individual cases was 
a major reason for the slower than expected recruitment 
rate. We collected screening logs during the trial, and they 
highlighted that the most common reason for not entering 
the trial was that the clinician and/or the patient wanted to 
either receive or avoid whole brain radiotherapy. Whilst we 
were unable to record any characteristics of these patients 
it does point to a lack of clinical equipoise, and it would be 
reasonable to think that patients with better prognoses were 
being selected for WBRT, and those with poorer prognoses 
were avoiding WBRT.
One of the unusual steps undertaken in QUARTZ was to 
release interim trial data to investigators (3,4). We believed 
that the lack of existing data was one of the main reasons 
for the lack of clinical equipoise, and having access to some 
data might make clinicians and patients more comfortable 
with the trial randomisation. It was interesting to note that 
after the presentation of these data to investigators, the 
rate at which poor performance status patients (KPS <70) 
were randomised into the trial dropped slightly (from 2.9 
patients per month to 2.2 per month), whereas the rate 
that good performance status patients were randomised 
increased significantly (from 3.2 patients per month to 
5.3 per month). This perhaps suggests that having viewed 
the interim data and seen the small size of any potential 
benefit, clinicians/patients became more comfortable with 
the possibility of omitting WBRT.
This links to another important point raised by 
Letter to the Editor
How do the QUARTZ trial results inform future research for patients 
with brain metastases from non-small cell lung cancer?
Matthew Nankivell1, Ruth E. Langley1, Rachael Barton2, Corinne Faivre-Finn3, Paula Wilson4, Elaine 
McColl5, Barbara Moore6, Iona Brisbane7, David Ardron8, Benjamin Sydes1, Richard Stephens1, Mahesh 
Parmar1, Paula Mulvenna9
1Medical Research Council Clinical Trials Unit at University College London, London, UK; 2Queen’s Centre for Oncology and Haematology, Castle 
Hill Hospital, Hull, UK; 3Radiotherapy Related Research, Division of Cancer Sciences, University of Manchester, Manchester Academic Health 
Science Centre, The Christie NHS Foundation Trust UK, Manchester, UK; 4Bristol Haematology and Oncology Centre, Bristol, UK; 5Newcastle 
Clinical Trials Unit and Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK; 6Wales Cancer Research Network, Cardiff 
UK; 7The Beatson West of Scotland Cancer Centre, Greater Glasgow Health Board and Clyde, Glasgow, UK; 8Patient representative, Manchester, 
UK; 9Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
Correspondence to: Matthew Nankivell. Medical Research Council Clinical Trials Unit at University College London, London, UK.  
Email: m.nankivell@ucl.ac.uk.
Provenance: This is an invited article commissioned by Section Editor Shaohua Cui (Department of Pulmonary Medicine, Shanghai Chest Hospital, 
Shanghai Jiao Tong University, Shanghai, China)。
Response to: Tsao MN. Should optimal supportive care alone be the standard of care for brain metastases patients from non-small cell lung cancer, who are 
not eligible for radiosurgery or surgery? Transl Cancer Res 2016;5:S1320-S1322.
Submitted Feb 24, 2017. Accepted for publication Feb 28, 2017.
doi: 10.21037/tcr.2017.03.08
View this article at: http://dx.doi.org/10.21037/tcr.2017.03.08
447
S447Translational Cancer Research, Vol 6, Suppl 2 March 2017
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2017;6(Suppl 2):S446-S447 tcr.amegroups.com
Tsao, that patients often have misconceptions about 
the intentions and potential outcomes of treatment. 
This was something described in this specific patient 
population by Dorman et al. (5), who interviewed nine 
QUARTZ patients from a single centre, several of whom 
demonstrated a misunderstanding of both the practical 
requirements of WBRT and their likely prognosis. In 
order for patients and clinicians to make fully informed 
treatment decisions, they need access to accurate estimates 
of likely treatment effects, and trials such as QUARTZ are 
the best source of this information.
The author also notes the emergence of several targeted 
agents during the life of QUARTZ. This is an important 
point, and these agents appear to be good options for 
patients with the appropriate molecular make-up (6). 
However at present only a small percentage of patients have 
a driver mutation targetable with approved treatment (in the 
UK approximately 10% of NSCLC patients have an EGFR 
mutation and 5% an ALK-rearrangement). Nonetheless 
it seems reasonable to believe that this will increase as our 
knowledge increases and more targets are identified. 
Two important outcomes from QUARTZ are: firstly 
that it is possible to conduct trials in this patient group; 
and secondly, that for the majority of patients, future trials 
of systemic agents can be conducted without also having 
to include WBRT. We agree with Tsao’s closing statement 
that the future of brain metastases research and treatment 
is promising, with increasing options and hopefully more 
opportunities for well conducted clinical trials.
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